News
Women with HR-positive breast cancer could use IVF without increased risk of recurrence- study
A new study examined pregnancy and cancer outcomes among patients who paused endocrine therapy to conceive

Using fertility preservation and assisted reproductive technologies such as IVF did not impact cancer recurrence rates among women with HR-positive breast cancer, a new study has shown.
Fertility preservation refers to methods intended to maintain the reproductive potential of the patient.
Such methods include ovarian stimulation for egg freezing, cryopreservation of ovarian tissue and the use of gonadotropin-releasing hormone analogs during chemotherapy to reduce the risk of premature ovarian failure.
Assisted reproductive technologies include various techniques to help the patient become pregnant, such as the transfer of cryopreserved embryos into a patient’s uterus, ovarian stimulation for IVF, intrauterine insemination, embryo or egg donation, ovarian tissue transplantation and clomiphene use.
“With the increasing age of childbearing, it is becoming more likely that women will be diagnosed with breast cancer before starting or completing their families,” said Dr Hatem A. Azim Jr, an adjunct professor at the School of Medicine and Breast Cancer Center at the Tecnológico de Monterrey in Mexico.
“Many breast cancer patients may opt for fertility preservation prior to starting cancer treatment and/or may use assisted reproductive technologies to increase their chances of pregnancy.”
Results from the POSITIVE trial presented at last year’s San Antonio Breast Cancer Symposium suggested that patients with HR-positive breast cancer could safely pause endocrine therapy for up to two years to become pregnant without increasing their risk of breast cancer recurrence.
However, the safety of conceiving after fertility preservation and/or assisted reproductive technologies for these patients remains unclear.
“There is a concern within the medical community that the use of fertility preservation or assisted reproductive technologies methods, particularly those that entail the use of hormones, could have detrimental effects on patients with HR-positive breast cancers,” Dr Azim noted.
To understand the impact of fertility preservation and assisted reproductive technologies, Azim and his colleagues conducted an analysis of outcomes from the POSITIVE trial.
Among the 497 evaluable participants who paused endocrine therapy to attempt pregnancy, 368 (74 per cent) became pregnant.
Among the patients who underwent some form of fertility preservation, 179 used embryo or oocyte cryopreservation prior to enrolment in the POSITIVE trial, while 215 used some form of assisted reproductive technology to attempt pregnancy. The most commonly used assisted reproductive technology was ovarian stimulation for IVF and cryopreserved embryo transfer.
The study found that younger age and cryopreserved embryo transfer were the factors most associated with higher chances of pregnancy, with 82.4 per cent of patients who underwent cryopreserved embryo transfer becoming pregnant.
Ovarian stimulation for cryopreservation, which precedes cryopreserved embryo transfer, was not associated with worse disease outcomes.
“Participants who underwent cryopreserved embryo transfer during the study had higher pregnancy rates with no apparent short-term detrimental impact on breast cancer outcome,” Azim explained.
Additional analyses found that menstrual cycles returned within six months of pausing endocrine therapy in most patients who had amenorrhea at trial entry and the type of adjuvant endocrine therapy the patient had received had no impact on the time to pregnancy.
Furthermore, the researchers found that younger patients became pregnant in a shorter time.
“We found that at two years after enrolment, 80 per cent of women younger than 35 years had a pregnancy compared to 50 per cent of those who were older than 40,” Azim said.
“Our data demonstrate the efficacy and short-term safety of different fertility preservation and assisted reproductive technology options, building on the primary results of the POSITIVE trial and providing vital information for fertility counselling of young breast cancer patients.”
To receive the Femtech World newsletter, sign up here.
Diagnosis
AI may help accelerate breast cancer diagnosis for high-risk women – study
Fertility
Infertility may be risk factor for early menopause, study suggests
News
Endometriosis documentary profiles stars including Marilyn Monroe and Amy Schumer

A non-profit has launched an endometriosis documentary featuring Amy Schumer and Marilyn Monroe as it pushes for changes in how the condition is treated and understood.
The Endometriosis Collective has launched to change how endometriosis is researched, treated and understood, starting with a documentary featuring stories from people including Amy Schumer and Marilyn Monroe.
The feature-length documentary, “End of the Cycle”, will premiere in New York on Tuesday, and The Endometriosis Collective is making the film free to stream online.
Schumer, a comedian, writer and actor, has previously spoken of how endometriosis left her “on the floor in pain, vomiting from the pain, the pain that nobody can see.”
Schumer is one of several celebrities featured in the documentary. Other contributors include dancer Julianne Hough, Olympic medallist Brittany Brown and actors Janel Parrish and Folake Olowofoyeku.
The Endometriosis Collective timed the documentary premiere to coincide with the 100th anniversary of Marilyn Monroe’s birth.
Monroe, who died in 1962, starred in films such as “Some Like It Hot” and “Gentlemen Prefer Blondes.”
According to a biography published in 1985, Monroe’s endometriosis was so severe that it destroyed her marriages, her wish for children, her career and ultimately her life.
The Endometriosis Collective said the documentary shares newly uncovered information about Monroe’s experience with endometriosis.
The non-profit said the information connects Monroe’s story to the experiences of women across generations, highlighting how far awareness, research and care still have to go.
A representative of the Marilyn Monroe Estate said: “By sharing this part of her story through ‘End of the Cycle,’ we hope to honour her legacy in a way that brings visibility to endometriosis, encourages more open dialogue and helps inspire the research needed to create change.”
As part of the premiere, The Endometriosis Collective is holding a panel discussion.
Schumer, Brown and Olowofoyeku, the documentary’s co-directors Sammy Jaye and Soraya Simi, and medical experts are due to be part of the premiere.
AbbVie’s Orilissa and Sumitomo Pharma’s Myfembree are among the approved drugs for endometriosis pain.
Hough, one of the participants in the documentary, starred in an Orilissa campaign in 2017.
Menopause1 week agoPerimenopause misinformation ‘putting women at risk’
Insight4 weeks agoNIH Grant terminations disproportionately impact minority scientists, research finds
Adolescent health4 weeks agoWUKA brings Period-Positive Pool Party to London Aquatics Centre to keep girls swimming through puberty
Hormonal health3 weeks agoPCOS renamed after decade-long campaign to end ‘cyst’ misconception
Events4 weeks agoWHIS 2026 unveils agenda and first speakers for the leading women’s health summit
Menopause4 weeks agoCBT shows promise for menopause insomnia and hot flashes
Hormonal health2 weeks agoNHS urged to update website following renaming of PCOS
News6 days agoThree menopause innovators shortlisted for Femtech World Award















3 Comments